Literature DB >> 14751408

Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide.

Leila Moezi1, Mehdi Rezayat, Morteza Samini, Hamed Shafaroodi, Shahram Ejtemaie Mehr, Mohammad R Ebrahimkhani, Ahmad R Dehpour.   

Abstract

Changes in vascular responsiveness are proposed as the basis for some of the cardiovascular complications in cholestasis. Cholestasis is also associated with accumulation of endogenous opioid peptides and evidence of nitric oxide (NO) overproduction. On the other hand, it is well known that anandamide, an endogenous cannabinoid ligand, causes hypotension and a decrease in systemic vascular resistance. In the present study, the possible role of the cannabinoid system in cholestasis-induced mesenteric vascular bed responsiveness was investigated. Mesenteric arteries of bile duct-ligated and sham-operated rats receiving daily administrations of saline were used for evaluating phenylephrine or anandamide dose-response, acute effects of N(G)-nitro-L-arginine methyl ester (L-NAME, 100 microM), a non-selective inhibitor of NO synthase (NOS), or naltrexone, an opioid receptors antagonist (1 microM). The other groups of bile duct-ligated and sham-operated rats received daily intraperitoneal administration of L-NAME (20 mg/kg/day), aminoguanidine, a selective inducible NOS (iNOS) inhibitor (150 mg/kg/day) or naltrexone (10 mg/kg/day). After 7 days, the superior mesenteric artery was cannulated and the mesenteric vascular bed was perfused according to the McGregor method. Anandamide-induced relaxation was significantly potentiated in mesenteric vascular beds of bile duct-ligated rats. Chronic treatment of bile duct-ligated animals with L-NAME and aminoguanidine blocked this hyperresponsiveness while the hyperresponsiveness was potentiated at large doses of anandamide on chronic treatment of these animals with naltrexone. Although acute L-NAME treatment of mesenteric beds completely blocked the anandamide-induced vasorelaxation in sham-operated rats, this vasorelaxation still was present in bile duct-ligated animals. Anandamide-induced vasorelaxation remained unaffected after acute naltrexone treatment of mesenteric beds in both bile duct-ligated and sham-operated rats. Our results indicate that (1) there is enhanced anandamide-induced vasorelaxation in cholestatic rats, probably due to a defect in cannabinoid or vanilloid receptors and (2) NO overproduction may be involved in cholestasis-induced vascular hyperresponsiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751408     DOI: 10.1016/j.ejphar.2003.12.004

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Protective effect of melatonin against multistress condition induced lipid peroxidation via measurement of gastric mucosal lesion and plasma malondialdehyde levels in rats.

Authors:  V Kiarostami; L Samini; M Ghazi-Khansari
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

Review 2.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

3.  Role of the nitric oxide pathway and the endocannabinoid system in neurogenic relaxation of corpus cavernosum from biliary cirrhotic rats.

Authors:  M Ghasemi; H Sadeghipour; H Shafaroodi; B G Nezami; T Gholipour; A R Hajrasouliha; S Tavakoli; M Nobakht; K P Moore; A R Mani; A R Dehpour
Journal:  Br J Pharmacol       Date:  2007-05-08       Impact factor: 8.739

4.  Opioid receptor blockade improves mesenteric responsiveness in biliary cirrhosis.

Authors:  Mohammad R Ebrahimkhani; Leila Moezi; Samira Kiani; Shahin Merat; Ahmad R Dehpour
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

5.  Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels.

Authors:  Maria Rosaria Romano; Marcello D Lograno
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.